BiotechTube

Alfuzosin + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neurogenic Urinary Bladder

Conditions

Neurogenic Urinary Bladder

Trial Timeline

Oct 1, 2007 → Dec 1, 2009

NCT ID
NCT00549939

About Alfuzosin + Placebo

Alfuzosin + Placebo is a phase 3 stage product being developed by Sanofi for Neurogenic Urinary Bladder. The current trial status is completed. This product is registered under clinical trial identifier NCT00549939. Target conditions include Neurogenic Urinary Bladder.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT00549939Phase 3Completed
NCT00336921Phase 2Completed

Competing Products

20 competing products in Neurogenic Urinary Bladder

See all competitors
ProductCompanyStageHype Score
MirabegronAstellas PharmaPhase 3
77
Solifenacin succinateAstellas PharmaPhase 3
77
Solifenacin succinateAstellas PharmaPhase 3
77
MirabegronAstellas PharmaPhase 1
33
mirabegronAstellas PharmaPhase 3
77
SAF312 + Placebo to SAF312NovartisPhase 2
52
4 mg Fesoterodine ER tablet from Zwickau + 4 mg fesoterodine ER tablet from Freiburg + 8 mg fesoterodine ER tablet from Zwickau + 8 mg fesoterodine ER tablet from FreiburgPfizerPhase 1
32
Fesoterodine PR 4 mg + Fesoterodine PR 8 mg + Fesoterodine BIC 2 mg + Fesoterodine BIC 4 mgPfizerPhase 3
76
Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B) + Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B) + Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B) + Fesoterodine BIC SR7 on apple sauce (Treatment D in Part A) + Fesoterodine BIC SR4 fed (Treatment E in Part B)PfizerPhase 1
32
Fesoterodine PR 4 mg + Fesoterodine PR 8 mg + Fesoterodine PR 8 mg + Oxybutynin + Fesoterodine PR + Fesoterodine BIC 2 mg + Fesoterodine BIC 4 mgPfizerPhase 3
76
alfuzosin (SL770499)SanofiPhase 3
76
Droxidopa capsules + Placebo capsulesLundbeckApproved
82
Rec 0/0438 1 mg or Rec 0/0438 2 mg + placeboRecordatiPhase 1/2
38
Ampreloxetine + PlaceboTheravance BiopharmaPhase 3
72
ampreloxetine + PlaceboTheravance BiopharmaPhase 3
72
ampreloxetine + PlaceboTheravance BiopharmaPhase 3
72
TD-9855 + PlaceboTheravance BiopharmaPhase 2
47
ampreloxetineTheravance BiopharmaPhase 3
72
Ampreloxetine <Dose A> + Ampreloxetine <Dose B> + Ampreloxetine Placebo + Moxifloxacin + Moxifloxacin PlaceboTheravance BiopharmaPhase 1
28
AmpreloxetineTheravance BiopharmaPhase 1
28

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84